|
|
|
|
Vol. 55, Issue 6, 1044-1048, June 1999
Department of Pharmaceutical Sciences, University of Montana,
Missoula, Montana (H.P.K., R.J.B.); and Department of Chemistry,
University of California, Irvine, California (A.R.C.)
Na+-dependent, high-affinity glutamate transporters in the
central nervous system are generally credited with regulating
extracellular levels of L-glutamate and maintaining
concentrations below those that would induce excitotoxic injury. Under
pathological conditions, however, it has been suggested that these same
transporters may contribute to excitotoxic injury by serving as sites
of efflux for cellular L-glutamate. In this study, we
examine the efflux of [3H]D-aspartate
from synaptosomes in response to both alternative substrates (i.e.,
heteroexchange), such as L-glutamate, and a metabolic
insult (5 mM potassium cyanide and 1 mM iodoacetate). Exposure
of synaptosomes containing [3H]D-aspartate to
either L-glutamate or metabolic inhibitors increased the
efflux of the radiolabeled substrate to over 200% of control values.
Two previously identified competitive transport inhibitors (L-trans-2,3-pyrrolidine dicarboxylate and
dihydrokainate) failed to stimulate
[3H]D-aspartate efflux but did inhibit
glutamate-mediated heteroexchange, consistent with the action of
nontransportable inhibitors. These compounds also attenuated the efflux
of [3H]D-aspartate from synaptosomes exposed
to the metabolic inhibitors. These results add further strength to the
model of central nervous system injury-induced efflux of
L-glutamate through its high-affinity transporters and
identify a novel strategy to attenuate this process.
This article has been cited by other articles:
![]() |
S. Colleoni, A. A. Jensen, E. Landucci, E. Fumagalli, P. Conti, A. Pinto, M. De Amici, D. E. Pellegrini-Giampietro, C. De Micheli, T. Mennini, et al. Neuroprotective Effects of the Novel Glutamate Transporter Inhibitor (-)-3-Hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]-isoxazole-4-carboxylic Acid, Which Preferentially Inhibits Reverse Transport (Glutamate Release) Compared with Glutamate Reuptake J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 646 - 656. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Cechova and Z. Zuo Inhibition of glutamate transporters increases the minimum alveolar concentration for isoflurane in rats Br. J. Anaesth., August 1, 2006; 97(2): 192 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Dabir, M. B. Robinson, E. Swanson, B. Zhang, J. Q. Trojanowski, V. M.-Y. Lee, and M. S. Forman Impaired Glutamate Transport in a Mouse Model of Tau Pathology in Astrocytes J. Neurosci., January 11, 2006; 26(2): 644 - 654. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Funicello, P. Conti, M. De Amici, C. De Micheli, T. Mennini, and M. Gobbi Dissociation of [3H]L-Glutamate Uptake from L-Glutamate-Induced [3H]D-Aspartate release by 3-Hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic Acid and 3-Hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-6-carboxylic Acid, Two Conformationally Constrained Aspartate and Glutamate Analogs Mol. Pharmacol., September 1, 2004; 66(3): 522 - 529. [Abstract] [Full Text] [PDF] |
||||